UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Kinase Fusion Gene:OSBPL9_CSNK2A2 |
Kinase Fusion Protein Summary |
Kinase Fusion gene summary |
Kinase Fusion partner gene information | Kinase Fusion gene name: OSBPL9_CSNK2A2 | KinaseFusionDB ID: KFG4364 | FusionGDB2.0 ID: KFG4364 | Hgene | Tgene | Gene symbol | OSBPL9 | CSNK2A2 | Gene ID | 114883 | 1459 | |
Gene name | oxysterol binding protein like 9 | casein kinase 2 alpha 2 | ||||||||||
Synonyms | ORP-9|ORP9 | CK2A2|CK2alpha'|CSNK2A1 | ||||||||||
Cytomap | 1p32.3 | 16q21 | ||||||||||
Type of gene | protein-coding | protein-coding | ||||||||||
Description | oxysterol-binding protein-related protein 9OSBP-related protein 9 | casein kinase II subunit alpha'CK II alpha'casein kinase 2 alpha'casein kinase 2, alpha prime polypeptide | ||||||||||
Modification date | 20240411 | 20240407 | ||||||||||
UniProtAcc | Q96SU4 | P19784 | ||||||||||
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000337809, ENST00000361556, ENST00000371710, ENST00000371714, ENST00000428468, ENST00000435686, ENST00000447887, ENST00000453295, ENST00000462759, ENST00000473207, ENST00000486942, ENST00000530544, ENST00000531828, | ENST00000262506, ENST00000566813, | |||||||||
Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: OSBPL9 [Title/Abstract] AND CSNK2A2 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | OSBPL9(52170854)-CSNK2A2(58202840), # samples:1 |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | CSNK2A2 | GO:0006302 | double-strand break repair | 22325354 |
Tgene | CSNK2A2 | GO:0018105 | peptidyl-serine phosphorylation | 28031292 |
Kinase Fusion gene breakpoints across OSBPL9 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Kinase Fusion gene breakpoints across CSNK2A2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
Kinase Fusion gene information. |
Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
ChiTaRS5.0 | CD653660 | OSBPL9 | chr1 | 52170854 | CSNK2A2 | chr16 | 58202840 |
Top |
Kinase Fusion ORF Analysis |
Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:52170854/:58202840) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
OSBPL9 | CSNK2A2 |
FUNCTION: Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine (PubMed:11239457, PubMed:11704824, PubMed:16193064, PubMed:30898438). Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection (PubMed:11704824, PubMed:16193064, PubMed:30898438). May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response (PubMed:12631575, PubMed:19387552, PubMed:19387551). During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage (PubMed:12631575, PubMed:19387552, PubMed:19387551). Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation (PubMed:11239457). Phosphorylates a number of DNA repair proteins in response to DNA damage, such as MDC1, RAD9A, RAD51 and HTATSF1, promoting their recruitment to DNA damage sites (PubMed:20545769, PubMed:21482717, PubMed:22325354, PubMed:26811421, PubMed:30898438, PubMed:35597237). Can also negatively regulate apoptosis (PubMed:19387552, PubMed:19387551). Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3 (PubMed:12631575, PubMed:19387552, PubMed:19387551). Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8 (PubMed:12631575, PubMed:19387552, PubMed:19387551). Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV (PubMed:12631575, PubMed:19387552, PubMed:19387551). Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, SRF, MAX, JUN, FOS, MYC and MYB (PubMed:12631575, PubMed:19387552, PubMed:19387551). Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function (PubMed:19387550). Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1 (PubMed:19387549). Acts as an ectokinase that phosphorylates several extracellular proteins (PubMed:12631575, PubMed:19387552, PubMed:19387551). During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV (PubMed:12631575, PubMed:19387552, PubMed:19387551). {ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11704824, ECO:0000269|PubMed:16193064, ECO:0000269|PubMed:20545769, ECO:0000269|PubMed:21482717, ECO:0000269|PubMed:22325354, ECO:0000269|PubMed:26811421, ECO:0000269|PubMed:30898438, ECO:0000269|PubMed:35597237, ECO:0000303|PubMed:12631575, ECO:0000303|PubMed:19387549, ECO:0000303|PubMed:19387550, ECO:0000303|PubMed:19387551, ECO:0000303|PubMed:19387552}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of OSBPL9_CSNK2A2 |
Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
CSNK2A2 | P19784 | human | CTNNB1 | P35222 | T112 | EGMQIPstQFdAAHP | |
CSNK2A2 | P19784 | human | SMC3 | Q9UQE7 | S1067 | GDVEGsQsQDEGEGs | SMC_N |
CSNK2A2 | P19784 | human | CSNK2B | P67870 | S3 | _____MsssEEVsWI | |
CSNK2A2 | P19784 | human | CCNH | P51946 | T315 | KHEEEEWtDDDLVEs | |
CSNK2A2 | P19784 | human | XRCC1 | P18887 | T523 | AGstDENtDsEEHQE | |
CSNK2A2 | P19784 | human | CDC37 | Q16543 | S13 | VWDHIEVsDDEDETH | CDC37_N |
CSNK2A2 | P19784 | human | CTNNB1 | P35222 | T102 | RAAMFPEtLDEGMQI | |
CSNK2A2 | P19784 | human | TP73 | O15350 | T27 | SSLEPDStyFDLPQS | |
CSNK2A2 | P19784 | human | TYMS | P04818 | S124 | FLDsLGFsTREEGDL | Thymidylat_synt |
CSNK2A2 | P19784 | human | NKX3-1 | Q99801 | T93 | EAEtLAEtEPERHLG | |
CSNK2A2 | P19784 | human | XRCC1 | P18887 | T488 | GAEDsGDtEDELRRV | |
CSNK2A2 | P19784 | human | SUZ12 | Q15022 | S583 | PQEMEVDsEDEKDPE | VEFS-Box |
CSNK2A2 | P19784 | human | SRPK1 | Q96SB4 | S555 | DYLFEPHsGEEYTRD | Pkinase |
CSNK2A2 | P19784 | human | XRCC1 | P18887 | S485 | QDNGAEDsGDtEDEL | |
CSNK2A2 | P19784 | human | SRPK1 | Q96SB4 | S51 | QEEEILGsDDDEQED | |
CSNK2A2 | P19784 | human | CTNNB1 | P35222 | S29 | VsHWQQQsyLDsGIH | |
CSNK2A2 | P19784 | human | XRCC1 | P18887 | S518 | GEDPyAGstDENtDs | |
CSNK2A2 | P19784 | human | XRCC1 | P18887 | T519 | EDPyAGstDENtDsE | |
CSNK2A2 | P19784 | human | NKX3-1 | Q99801 | T89 | AAPEEAEtLAEtEPE | |
CSNK2A2 | P19784 | human | HSF1 | Q00613 | T142 | DsVTKLLtDVQLMKG | |
CSNK2A2 | P19784 | human | CSNK2B | P67870 | S2 | ______MsssEEVsW |
Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
Enriched GO biological processes of the phosphorylation target genes of the kinase |
Kinase | GOID | GO term | P.adjust |
CSNK2A2 | ID | Description | 0.00e+00 |
CSNK2A2 | GO:0009410 | response to xenobiotic stimulus | 1.05e-04 |
CSNK2A2 | GO:0060768 | regulation of epithelial cell proliferation involved in prostate gland development | 6.06e-03 |
CSNK2A2 | GO:0060767 | epithelial cell proliferation involved in prostate gland development | 6.06e-03 |
CSNK2A2 | GO:0048709 | oligodendrocyte differentiation | 7.47e-03 |
CSNK2A2 | GO:0003159 | morphogenesis of an endothelium | 7.47e-03 |
CSNK2A2 | GO:0061154 | endothelial tube morphogenesis | 7.47e-03 |
CSNK2A2 | GO:0060479 | lung cell differentiation | 1.55e-02 |
CSNK2A2 | GO:0060487 | lung epithelial cell differentiation | 1.55e-02 |
CSNK2A2 | GO:1901654 | response to ketone | 2.68e-02 |
CSNK2A2 | GO:0060428 | lung epithelium development | 2.69e-02 |
CSNK2A2 | GO:0033574 | response to testosterone | 2.69e-02 |
CSNK2A2 | GO:0048713 | regulation of oligodendrocyte differentiation | 2.69e-02 |
CSNK2A2 | GO:0030850 | prostate gland development | 3.02e-02 |
CSNK2A2 | GO:0010001 | glial cell differentiation | 3.02e-02 |
CSNK2A2 | GO:0007062 | sister chromatid cohesion | 3.65e-02 |
CSNK2A2 | GO:0006303 | double-strand break repair via nonhomologous end joining | 3.65e-02 |
CSNK2A2 | GO:0001666 | response to hypoxia | 3.65e-02 |
CSNK2A2 | GO:0051054 | positive regulation of DNA metabolic process | 3.65e-02 |
CSNK2A2 | GO:0001655 | urogenital system development | 3.65e-02 |
CSNK2A2 | GO:0001822 | kidney development | 3.65e-02 |
CSNK2A2 | GO:0036293 | response to decreased oxygen levels | 3.65e-02 |
CSNK2A2 | GO:0030858 | positive regulation of epithelial cell differentiation | 3.65e-02 |
CSNK2A2 | GO:0097193 | intrinsic apoptotic signaling pathway | 3.65e-02 |
CSNK2A2 | GO:0072001 | renal system development | 3.66e-02 |
CSNK2A2 | GO:0060562 | epithelial tube morphogenesis | 3.68e-02 |
CSNK2A2 | GO:0042063 | gliogenesis | 3.68e-02 |
CSNK2A2 | GO:0045685 | regulation of glial cell differentiation | 3.68e-02 |
CSNK2A2 | GO:0070482 | response to oxygen levels | 3.69e-02 |
CSNK2A2 | GO:0000079 | regulation of cyclin-dependent protein serine/threonine kinase activity | 3.69e-02 |
CSNK2A2 | GO:1904029 | regulation of cyclin-dependent protein kinase activity | 3.83e-02 |
CSNK2A2 | GO:0048525 | negative regulation of viral process | 4.38e-02 |
CSNK2A2 | GO:0001656 | metanephros development | 4.38e-02 |
CSNK2A2 | GO:0032204 | regulation of telomere maintenance | 5.19e-02 |
CSNK2A2 | GO:0014013 | regulation of gliogenesis | 5.63e-02 |
CSNK2A2 | GO:0032355 | response to estradiol | 5.76e-02 |
CSNK2A2 | GO:0048732 | gland development | 5.87e-02 |
CSNK2A2 | GO:0010720 | positive regulation of cell development | 5.87e-02 |
CSNK2A2 | GO:0002065 | columnar/cuboidal epithelial cell differentiation | 6.05e-02 |
CSNK2A2 | GO:0021761 | limbic system development | 6.05e-02 |
CSNK2A2 | GO:0002761 | regulation of myeloid leukocyte differentiation | 6.05e-02 |
CSNK2A2 | GO:0045931 | positive regulation of mitotic cell cycle | 6.17e-02 |
CSNK2A2 | GO:0048565 | digestive tract development | 6.17e-02 |
CSNK2A2 | GO:0003158 | endothelium development | 6.17e-02 |
CSNK2A2 | GO:1903900 | regulation of viral life cycle | 6.17e-02 |
CSNK2A2 | GO:0051053 | negative regulation of DNA metabolic process | 6.17e-02 |
CSNK2A2 | GO:0055123 | digestive system development | 6.17e-02 |
CSNK2A2 | GO:0007584 | response to nutrient | 6.17e-02 |
CSNK2A2 | GO:0000723 | telomere maintenance | 6.17e-02 |
CSNK2A2 | GO:0048754 | branching morphogenesis of an epithelial tube | 6.17e-02 |
Top |
Related Drugs to OSBPL9_CSNK2A2 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Distribution of the number of studies mentioning OSBPL9-CSNK2A2 and kinase inhibitors the PubMed Abstract (04-01-2024) |
Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to OSBPL9_CSNK2A2 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
MeSH ID | MeSH term |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
Clinical Trials from clinicaltrials.gov (06-17-2024) |
Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |